Comparative Pharmacology
Head-to-head clinical analysis: PHERAZINE DM versus VASOCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHERAZINE DM versus VASOCON A.
PHERAZINE DM vs VASOCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phererazine DM is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic properties) and dextromethorphan (a non-opioid antitussive that acts on the sigma-1 receptor and NMDA receptor antagonist). Promethazine blocks H1 receptors and reduces histamine-mediated symptoms, while dextromethorphan suppresses cough by central action on the cough center.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
Adults: 1 tablet (promethazine 25 mg / dextromethorphan 30 mg) orally every 6-8 hours as needed; maximum 4 tablets per day.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in children; 5-6 hours in adults; up to 8 hours in elderly. Clinical context: Dosing interval adjustment needed in renal impairment.
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Primarily renal: 60-70% as unchanged drug and glucuronide conjugate; 15-20% fecal via biliary excretion.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Category C
Category C
Antitussive/Antihistamine Combination
Ophthalmic Decongestant/Antihistamine Combination